Consumer News Eli Lilly Says Its New Diabetes Drug Was 94 Effective In Clinical Trials
Search Related Content
Sorry, Your Requested Page Was Not Found. Greetings! We apologize for the inconvenience, but the page, Consumer News Eli Lilly Says Its New Diabetes Drug Was 94 Effective In Clinical Trials is no longer available. Please use our search box below to find related content and browse the list of related news stories. Depending on the topic, news articles are deleted 3-18 months after their creation date. We prefer to keep content fresh and current, rather than holding onto outdated news. Thanks for visiting today.Search RobinsPost News & Noticias
Eli Lilly Says Oral GLP-1 Drug Reduced Blood Sugar Levels In Two Late-Stage Trials
Eli Lilly and Company (LLY) on Wednesday said that its oral GLP-1 drug Orforglipron lowered blood glucose levels in two late-stage trials, confirming its potential in treating type-2 diabetes. While ... Read More
Eli Lilly oral weight loss drug orforglipron succeeds in late-stage trials for diabetes
Eli Lilly (NYSE:LLY) announced on Wednesday that its oral weight loss candidate, orforglipron, reached the main goals in two Phase 3 trials for patients with type 2 diabetes, indicating its potential ... Read More
Eli Lilly's Weight-Loss Drug Meets Primary Endpoint in Diabetes Trials
Eli Lilly said its investigational oral GLP-1 weight-loss drug, orforglipron, met its primary endpoints in two recent phase 3 trials. The medicine company said Wednesday the drug met the primary and ... Read More
Eli Lilly's orforglipron bests Farxiga, padding oral GLP-1 case with pair of phase 3 diabetes wins
Eli Lilly has guided its oral GLP-1 drug candidate orforglipron through two more late-phase tests in Type 2 diabetes, racking up wins against placebo and AstraZeneca’s Farxiga to stay on track to seek ... Read More
Blow Us A Whistle
Comments (Whistles) Designed By Disqus